Grand Pharma’s self-developed global innovative RDC drug GPN01530 gets FDA clinical clearance for solid tumor diagnosis, with InnoStar supporting via non-clinical studies.

BoomRay's globally first targeted covalent radiopharmaceutical wins China's clinical trial approval, with InnoStar supporting its progress via non-clinical studies.

InnoStar's professional team ensured the reliability and integrity of the experimental data through a scientifically rigorous approach and highly efficient, precise technical operations. This provided critical data support for the successful clinical approval of Lutetium [177Lu]-BL-ARC001 Injection, accelerating the project's progress.

InnoStar Shanghai will be participating as a key partner at the 23rd SABPA BioPharma Conference, taking place on October 4, 2025, in San Diego, California.

August 11, 2025: NEUREGEN's NRG-103, the world's first in situ transdifferentiation-based gene therapy for glioblastoma, received FDA IND approval, with non-clinical support from InnoStar aiding the approval.

​​InnoStar and Cyberiad-Life developed a 3D-bioprinted mouse testicular organoid model, enabling in vitro reproductive toxicity screening, featured in ACS Biomater. Sci. Eng.​​